A new trading day began on Monday, with AbCellera Biologics Inc (NASDAQ: ABCL) stock price up 6.25% from the previous day of trading, before settling in for the closing price of $2.72. ABCL’s price has ranged from $2.34 to $6.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 387.52% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 10.68%. With a float of $206.59 million, this company’s outstanding shares have now reached $290.82 million.
In an organization with 586 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -85.51%, operating margin of -814.68%, and the pretax margin is -540.95%.
AbCellera Biologics Inc (ABCL) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of AbCellera Biologics Inc is 29.89%, while institutional ownership is 33.36%.
AbCellera Biologics Inc (ABCL) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.1 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.68% per share during the next fiscal year.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Here are AbCellera Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.53, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Let’s dig in a bit further. During the last 5-days, its volume was 2.15 million. That was better than the volume of 1.62 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.14%. Additionally, its Average True Range was 0.14.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 35.92%, which indicates a significant decrease from 94.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.59% in the past 14 days, which was lower than the 56.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.61, while its 200-day Moving Average is $3.67. However, in the short run, AbCellera Biologics Inc’s stock first resistance to watch stands at $2.95. Second resistance stands at $3.01. The third major resistance level sits at $3.12. If the price goes on to break the first support level at $2.79, it is likely to go to the next support level at $2.68. The third support level lies at $2.62 if the price breaches the second support level.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
With a market capitalization of 851.60 million, the company has a total of 294,054K Shares Outstanding. Currently, annual sales are 38,030 K while annual income is -146,400 K. The company’s previous quarter sales were 7,320 K while its latest quarter income was -36,930 K.
